Expertise in
25
conditions

Dr. Susan C. Modesitt

Gynecologic Oncology | Oncology
The Emory Clinic Inc
1365 Clifton Rd Ne, 
Atlanta, GA 
Accepting New Patients
Offers Telehealth
Expertise in
25
conditions
The Emory Clinic Inc
1365 Clifton Rd Ne, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Susan Modesitt is a Gynecologic Oncologist and an Oncologist in Atlanta, Georgia. Dr. Modesitt is highly rated in 25 conditions, according to our data. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, BRCA Positive Breast Cancer, Salpingo-Oophorectomy, and Oophorectomy. Dr. Modesitt is currently accepting new patients.

Her clinical research consists of co-authoring 87 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Licenses
Obstetrics & Gynecology in VA
Hospital Affiliations
Emory University Hospital Midtown
Emory University Hospital
Emory Hillandale Hospital
Emory Decatur Hospital
Saint Joseph's Hospital Of Atlanta, Inc
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS
View 1 Less Insurance Carrier -

Locations

THE EMORY CLINIC INC
1365 Clifton Rd Ne, Atlanta, GA 30322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: May 20, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: October 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Enrollment Status: Completed
Publish Date: October 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

87 Total Publications

The time is now: Concrete actions are needed to improve diversity and representation in clinical trials participation.
The time is now: Concrete actions are needed to improve diversity and representation in clinical trials participation.
Journal: Gynecologic oncology reports
Published: October 14, 2024
Similar Doctors
Expertise in
36
conditions
Dr. Sharad A. Ghamande
Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Expertise in
36
conditions
Dr. Sharad A. Ghamande
Gynecologic Oncology | Obstetrics and Gynecology | Oncology

Wellstar Medical Group LLC

5150 Stilesboro N W Rd, Suite 220, 
Kennesaw, GA 
 (25.9 mi)
770-424-8222
Languages Spoken:
English, Sign Language, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sharad Ghamande is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Kennesaw, Georgia. Dr. Ghamande is highly rated in 36 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Oophorectomy, and Salpingo-Oophorectomy. Dr. Ghamande is currently accepting new patients.

Expertise in
17
conditions
Dr. Suresh S. Ramalingam
Oncology
Expertise in
17
conditions
Dr. Suresh S. Ramalingam
Oncology

The Emory Clinic Inc

1365 Clifton Rd Ne, 
Atlanta, GA 
 (0.1 mi)
404-778-7525
Languages Spoken:
English, Tamil
See accepted insurances
Accepting New Patients
Offers Telehealth

Suresh Ramalingam is an Oncologist in Atlanta, Georgia. Dr. Ramalingam is highly rated in 17 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Ramalingam is currently accepting new patients.

Expertise in
13
conditions
Dr. Jennifer M. Scalici
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Expertise in
13
conditions
Dr. Jennifer M. Scalici
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

The Emory Clinic Inc

1365 Clifton Rd Ne, 
Atlanta, GA 
 (0.1 mi)
404-778-7525
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jennifer Scalici is a Gynecologic Oncologist and an Oncologist in Atlanta, Georgia. Dr. Scalici is highly rated in 13 conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Malignant Mixed Mullerian Tumor, Lump in the Abdomen, Hysterectomy, and Lymphadenectomy. Dr. Scalici is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Modesitt's expertise for a condition
ConditionClose
View All 19 Advanced Conditions
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile